Skip to main content
GutCited

Alpha-Galactosidase 用于 Irritable Bowel Syndrome (IBS)

D

Single study in IBS patients consuming high-FODMAP diet. May reduce gas-related symptoms from specific food triggers.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dalpha\u002Dgalactosidase\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

D

结论

Single study in IBS patients consuming high-FODMAP diet. May reduce gas-related symptoms from specific food triggers.

Key Study Findings

Review
Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review.
Dose: None vs: None Outcome: None 效果: None None

研究人群: None

Randomized Controlled Trial Double-blind
A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal …
Dose: 1200 G vs: placebo Outcome: every 30 min during 7 效果: None None

研究人群: patients with ibs after three standardized

Randomized Controlled Trial n=31 2.0 weeks Double-blind
Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment.
Dose: 300 GALU or 150 GALU vs: Placebo (glucose) Outcome: GI symptom severity on VAS 效果: None pP0.006

研究人群: IBS patients (Rome III, H2 producers)

Randomized Controlled Trial n=125 4 weeks Double-blind
Does oral α-galactosidase relieve irritable bowel symptoms?
Dose: alpha-galactosidase 600 GalU per meal vs: placebo Outcome: overall IBS symptom relief 效果: no significant difference vs placebo >0.05

研究人群: IBS patients

Key Statistics

1

研究数量

60

受试者

Positive

D

等级

Referenced Papers

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

常用剂量

general:
150-300 GalU (alpha-galactosidase units) per serving of gas-producing foods
standardbeanodose:
300 GalU (2-3 tablets) with first bite of problem food

上限: No established upper limit; adjust per meal as needed

研究中使用的剂量

剂量 持续时间 效果 N
None -- Mixed --
1200 G -- Neutral --
300 GALU or 150 GALU 2.0 weeks Positive 31
alpha-galactosidase 600 GalU per meal 4 weeks Neutral 125

最佳服用时间: With the first bite of gas-producing food

Safety & Side Effects

已报告的副作用

  • Generally very well-tolerated
  • Rare allergic reactions to mold-derived enzyme (Aspergillus source)
  • May cause mild GI discomfort in rare cases

已知相互作用

  • Acarbose (alpha-galactosidase may counteract the blood sugar-lowering mechanism of acarbose; contraindicated for concurrent use)
  • Miglitol (similar mechanism conflict as acarbose)

可耐受最高摄入量: No established upper limit; adjust per meal as needed

在开始服用任何补充剂之前,请务必咨询您的医疗保健提供者。

Frequently Asked Questions

Does Alpha-Galactosidase help with Irritable Bowel Syndrome (IBS)?
Based on 1 studies with 60 participants, there is preliminary evidence that needs more research that Alpha-Galactosidase may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).
How much Alpha-Galactosidase should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 150-300 GalU (alpha-galactosidase units) per serving of gas-producing foods. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Alpha-Galactosidase?
Reported side effects may include Generally very well-tolerated, Rare allergic reactions to mold-derived enzyme (Aspergillus source), May cause mild GI discomfort in rare cases. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Alpha-Galactosidase and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 1 peer-reviewed studies with 60 total participants. The overall direction of effect is positive.

Related Evidence

FDA 免责声明: 这些声明未经美国食品药品监督管理局(FDA)评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析,不构成医疗建议。在开始任何补充剂方案之前,请务必咨询您的医疗保健提供者。